For laboratory research use only. This article summarises published preclinical literature. BPC-157 is not approved for human use in the UK or any other jurisdiction and is sold by Velyx Research Ltd strictly as a research compound.
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide — a chain of exactly fifteen amino acids — with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). Its molecular weight is 1,419.53 daltons, its molecular formula is C₆₂H₉₈N₁₆O₂₂, and its CAS registry number is 137525-51-0.
The compound was isolated from a larger protein — designated Body Protection Compound (BPC) — found in human gastric juice. The specific fifteen-amino-acid fragment now known as BPC-157 was identified by researchers at the University of Zagreb, Croatia, led by Professor Predrag Sikiric, whose group first described its gastroprotective properties in 1992 (Sikiric et al., Acta Physiologica Hungarica, 1992). The designation "157" refers to the positional sequence within the parent protein from which this fragment was selected.
The peptide sequence shows no significant homology with other known proteins, which makes it a structurally distinct research subject. One of its most notable characteristics from a laboratory handling perspective is its stability: BPC-157 remains intact in human gastric juice for more than 24 hours, a property that distinguishes it from most peptides, which are rapidly degraded under acidic conditions (Veljaca et al., 1995). This stability is relevant to researchers studying oral bioavailability and systemic delivery mechanisms.
BPC-157 is not approved for clinical use by any regulatory authority, including the MHRA in the UK, the FDA in the United States, or the EMA in the European Union. It has been classified as a Category 2 bulk drug substance by the FDA (2023), meaning licensed compounding pharmacies cannot produce it. The World Anti-Doping Agency added it to its prohibited list in 2022 under the S0 category of non-approved substances, though it was not carried forward to subsequent prohibited lists. All published evidence for its biological activity in tissue models derives from preclinical research, predominantly in rodent models.
Molecular Mechanisms: How BPC-157 Acts on Cells
The research literature identifies several intersecting signalling pathways through which BPC-157 appears to exert its documented preclinical effects. These mechanisms are not mutually exclusive — they operate concurrently and appear to reinforce one another in tissue injury models.
The VEGFR2–Akt–eNOS Axis
The most extensively characterised mechanism involves the vascular endothelial growth factor receptor 2 (VEGFR2) signalling cascade. Hsieh et al. (2017), publishing in the Journal of Molecular Medicine, demonstrated that BPC-157 upregulates VEGFR2 expression on vascular endothelial cells and activates downstream Akt phosphorylation, which in turn stimulates endothelial nitric oxide synthase (eNOS) activity. This cascade promotes nitric oxide (NO) production, endothelial cell migration, and new vessel formation.
The same research group published a follow-up study in Scientific Reports (Hsieh et al., 2020) examining the Src-Caveolin-1-eNOS pathway specifically. Using isolated aortic tissue preparations and cultured endothelial cells, they showed that BPC-157 at a concentration of 1 μg/ml increased nitric oxide production by a factor of 1.35 compared to controls, measured using DAF-FM DA fluorescence. The study further demonstrated that BPC-157-enhanced cell migration was completely suppressed when hemoglobin was added to chelate nitric oxide, confirming that NO is a necessary mediator of the observed migratory effect.
The FAK-Paxillin Signalling Pathway
A second major mechanism identified in the literature involves focal adhesion kinase (FAK) and its binding partner paxillin — proteins central to cytoskeletal reorganisation, cell adhesion, and directed cell migration.
Chang et al. (2011), publishing in the Journal of Applied Physiology (PMID: 21030672), examined BPC-157 in tendon fibroblasts isolated from rat Achilles tendons. Cells treated with BPC-157 at concentrations of 1 μg/ml and 2 μg/ml for 24 hours showed dose-dependent increases in phospho-FAK and phospho-paxillin, measured by Western blot, with no change in total FAK or paxillin protein levels. The study also demonstrated that BPC-157-treated tendon fibroblasts showed significantly accelerated ex vivo outgrowth from tendon explants, enhanced cell survival under hydrogen peroxide stress, and increased transwell filter migration in a dose-dependent manner. Critically, direct cell proliferation as measured by MTT assay was not affected, suggesting the mechanism is primarily migratory rather than mitogenic.
A 2019 study by Wang et al. in Rehabilitation Practice and Science replicated and extended these findings in skeletal muscle cells, showing BPC-157-treated cells exhibited upregulated paxillin and vinculin expression alongside enhanced migration and spreading, consistent with FAK-paxillin pathway activation across tissue types beyond tendon.
Growth Hormone Receptor Upregulation
Chang et al. (2014), publishing in Molecules, demonstrated through cDNA microarray analysis that growth hormone receptor (GHR) was among the most significantly upregulated genes in tendon fibroblasts treated with BPC-157. The study showed dose- and time-dependent increases in GHR expression at both mRNA and protein level, and further demonstrated that growth hormone added to BPC-157-pretreated cells produced amplified proliferative responses compared to either treatment alone. The authors noted the effect persisted for at least three days in cultured cells, consistent with BPC-157's documented stability profile.
Nitric Oxide System Modulation
Beyond eNOS activation, BPC-157 demonstrates a more complex modulatory relationship with the nitric oxide system. Sikiric and colleagues have published extensively on what they describe as a bidirectional modulatory effect: BPC-157 appears to downregulate the inducible nitric oxide synthase (iNOS/NOS2) isoform — associated with pathological inflammation and tissue-damaging nitric oxide overproduction — while upregulating the constitutive eNOS isoform associated with vascular homeostasis (reviewed in Sikiric et al., Nitric Oxide: From Research to Therapeutics, Springer Nature, 2023).
A 2025 commentary published in Pharmaceuticals (Sikiric et al., 2025), responding to a toxicology review by Józwiak et al., argued that this differential modulation of nitric oxide pathways is mechanistically distinct from the pro-tumourigenic angiogenesis described by Folkman, and that the available preclinical data does not support the theoretical carcinogenesis risk proposed by critics. This remains an area of active scientific debate, and researchers working with BPC-157 should be aware of it as an open question in the literature.
Published Preclinical Study Findings
Tendon and Ligament Research
The earliest published animal work on BPC-157 in musculoskeletal tissue dates to 1993, with systematic study of tendon models beginning in the early 2000s. Staresinic et al. (2003), publishing in the Journal of Orthopaedic Research, examined BPC-157 in a rat Achilles tendon transection model. The study reported enhanced biomechanical properties, improved collagen fibre organisation, and accelerated restoration of load-bearing capacity in treated animals compared to saline controls.
A 2019 narrative review by Gwyer, Wragg and Wilson in Cell and Tissue Research synthesised the available musculoskeletal literature to that date, concluding that across all reviewed studies investigating BPC-157 in tendon, ligament, and skeletal muscle models, results were "consistently positive and prompt," with healing observed across both traumatic and systemic injury conditions.
A 2025 systematic review by Vasireddi et al., published in a peer-reviewed orthopaedic journal and indexed in PubMed (PMID: PMC12313605), identified 36 studies from 1993 to 2024 examining BPC-157 in musculoskeletal contexts. The authors reported that across these studies, BPC-157 was associated with improved outcomes in muscle, tendon, ligament, and bone injury models, attributing the mechanism principally to VEGFR2-mediated angiogenesis and FAK-paxillin-dependent fibroblast activity.
Gastrointestinal Models
BPC-157's origins are in gastric biology, and this remains one of the most thoroughly studied areas. In gastric ulcer models, BPC-157 administration has been associated with accelerated mucosal restitution, reduction in lesion area, and normalisation of gastric acid secretion parameters. Park et al. (2020), publishing in Current Pharmaceutical Design, examined BPC-157's role in protecting against NSAID-induced intestinal damage, reporting stabilisation of intestinal permeability markers and reduction in cytotoxic injury in rat models.
Vascular and Ischaemia-Reperfusion Models
Sikiric et al. (2022), in the World Journal of Gastroenterology (PMID: 35125818), summarised evidence from multiple rat models showing BPC-157 administration resolved major vessel occlusion disturbances — including hepatic ischaemia-reperfusion injury and portal vein constriction models — through promotion of collateral vessel formation and reduction of portal hypertension markers.
Central Nervous System Models
Vukojevic et al. (2022), in Neural Regeneration Research, reviewed preclinical evidence of BPC-157 activity in CNS models, including stroke and hippocampal ischaemia-reperfusion studies in rats. In the stroke model specifically, BPC-157 administered during reperfusion was associated with improved performance on the Morris water maze, inclined beam-walking, and lateral push tests at both 24-hour and 72-hour timepoints.
The Human Data: Extremely Limited
Researchers should note that human evidence for BPC-157 is minimal. Across the entire published literature, fewer than 50 humans have been studied in any BPC-157 research context. Three small pilot studies exist: a retrospective case series examining intra-articular injection for knee pain (Lee & Padgett, 2021, Alternative Therapies in Health and Medicine); a pilot study of BPC-157 in interstitial cystitis (Lee et al., 2024); and a 2025 report describing intravenous administration in two healthy adults without reported adverse events (Lee et al., 2025). None of these studies were randomised controlled trials. All appeared in the same journal and none provide sufficient evidence to draw conclusions about human efficacy or safety. A Phase I clinical trial (NCT02637284) was initiated in 2015, but results have not been published in a peer-reviewed journal.
This is a fundamental limitation. Preclinical findings in rodent models do not reliably predict human outcomes, and researchers working with BPC-157 in any in vitro or ex vivo model should be explicit about this constraint in their study design and reporting.
Laboratory Reconstitution Protocol
BPC-157 is supplied in lyophilised (freeze-dried) powder form in sealed glass vials, standardly at 5mg quantities. The following represents standard laboratory reconstitution practice. All handling should be conducted under sterile conditions appropriate to the research context.
Required materials: Bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative), 1ml or 3ml syringes, 23–25 gauge needles, the sealed vial of lyophilised BPC-157.
Step 1 — Preparation. Allow the vial to reach ambient temperature before opening if refrigerated. Do not shake.
Step 2 — Volume calculation. Determine the concentration required for your experimental protocol. A common working concentration is 1mg/ml, which requires adding 5ml of bacteriostatic water to a 5mg vial.
Step 3 — Reconstitution. Draw the calculated volume of bacteriostatic water into the syringe. Insert the needle through the rubber septum of the BPC-157 vial and inject the water slowly, directing the stream against the interior wall of the vial rather than directly onto the lyophilised cake. Do not inject into the powder under pressure.
Step 4 — Dissolution. Gently swirl the vial in a circular motion until the powder is fully dissolved. Do not vortex or shake vigorously — mechanical agitation can denature the peptide.
Step 5 — Visual inspection. The reconstituted solution should be clear and colourless. Any cloudiness, particulate matter, or discolouration indicates the sample should not be used.
Step 6 — Aliquoting. For experiments requiring multiple administrations, aliquot the reconstituted solution into smaller volumes to avoid repeated freeze-thaw cycles of the same sample.
Storage Requirements
Lyophilised BPC-157 (unreconstituted) should be stored at -20°C for long-term stability. Under these conditions, the compound remains stable for up to 24 months from the date of manufacture as documented by the manufacturer's COA. Short-term storage at 2–8°C (refrigerated, not frozen) for up to 30 days is acceptable for unreconstituted lyophilate.
Once reconstituted with bacteriostatic water, the solution should be stored at 2–8°C and used within 28 days. Bacteriostatic water's preservative action inhibits microbial growth over this period. Reconstituted solution should not be stored at -20°C as repeated freeze-thaw cycles degrade the peptide structure.
Do not expose BPC-157 in any form to direct sunlight. Store in opaque or amber containers where possible. All Velyx Research Ltd shipments include cold-pack insulation to maintain the cold chain during transit; refrigerate upon receipt.
Purity Standards and What They Mean
Research-grade BPC-157 is characterised primarily by HPLC (high-performance liquid chromatography) purity — expressed as a percentage — which measures the proportion of the sample consisting of the target peptide sequence versus impurities, degradation products, and synthesis byproducts.
A purity of 99%+ is the industry standard for research-grade compounds and is the minimum specification for Velyx Research Ltd products. Lower purity grades introduce variables that complicate experimental interpretation — if 5% of a sample consists of unknown impurities, any observed biological effect cannot be confidently attributed to BPC-157 alone.
HPLC purity is typically assessed by reversed-phase HPLC, in which the sample is passed through a chromatography column that separates components by hydrophobicity. The area under each peak in the resulting chromatogram corresponds to the relative proportion of each component. The stated purity percentage represents the target peptide's peak area as a proportion of total peak area.
Regulatory and Compliance Context (UK)
BPC-157 is not a controlled substance under the Misuse of Drugs Act 1971 in the UK and is not scheduled under the Psychoactive Substances Act 2016. Possession is not a criminal offence.
However, BPC-157 is not licensed as a medicine in the UK and has not received Marketing Authorisation from the MHRA. Under the Human Medicines Regulations 2012, it is illegal to sell, supply, or market any substance as a medicinal product for human consumption without MHRA authorisation. Velyx Research Ltd sells BPC-157 exclusively as a research compound for laboratory use, with no claims made regarding therapeutic application. All purchasers confirm upon ordering that the compound is for research purposes only and will not be used for human or veterinary consumption.
Researchers should note that the UK regulatory landscape for novel research compounds is subject to ongoing review. We recommend consulting current MHRA guidance at mhra.gov.uk for the most current regulatory position.
Key Published References
Chang, C.H., Tsai, W.C., Lin, M.S., Hsu, Y.H., & Pang, J.H.S. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780. PMID: 21030672.
Chang, C.H., Tsai, W.C., Hsu, Y.H., & Pang, J.H. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 19(12), 19066–19077.
Gwyer, D., Wragg, N.M., & Wilson, S.L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153–159.
Hsieh, M.J., Liu, H.T., Wang, C.N., et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 95(3), 323–333.
Hsieh, M.J., Lee, C.H., Chueh, H.Y., et al. (2020). Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports, 10, 17078.
Józwiak, M. et al. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals, 18(2), 185.
Sikiric, P. et al. (2022). Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances. World Journal of Gastroenterology, 28(1), 23–46. PMID: 35125818.
Vasireddi, N. et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. PubMed: PMC12313605.
Vukojevic, J. et al. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research, 17, 482–487.
Wang, S.H., Lin, L.P., Lin, M.S., Pang, J.H.S., & Tsai, W.C. (2019). BPC 157 promotes skeletal muscle cells migration in association with up-regulation of paxillin and vinculin expression. Rehabilitation Practice and Science, 47(1).
This article is provided for informational and educational purposes relating to published scientific research. It does not constitute medical advice. BPC-157 is sold by Velyx Research Ltd for laboratory research use only and is not for human or veterinary consumption. Velyx Research Ltd makes no claims regarding therapeutic efficacy in humans.